Study of the Effectiveness of The COVID-19 Vaccine

NCT05766176 | Completed DMC

• 1 other identifier: NAP04
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This descriptive study examines neutralizing antibody levels against COVID-19 in health workers before and after the 2nd booster of the COVID-19 vaccine in Surakarta, Indonesia.

Conditions

COVID-19

Keywords

COVID-19 Vaccine, Health Worker

Outcome Measures

Primary Outcomes (1)

• quantitative anti-sars-cov-2 titers

  The quantitative Anti-SARS-CoV-2 test is an examination to measure in vitro quantitative antibodies (including IgG) against the receptor binding domain (RBD) of the SARS-CoV-2 Spike protein (S) which aims to assess the adaptive humoral immune response to the SARS-CoV-2 Spike protein. Measurement with the ECLIA method. Ratio Scale

  Change of quantitative anti-sars-cov-2 titers before the second booster of vaccination COVID-19 and one month after

Study Arms (1)

Health worker

A health worker who received a second dose of booster COVID19 vaccine

Diagnostic Test: COVID-19 Antibody

Interventions

COVID-19 Antibody DIAGNOSTIC_TEST

This descriptive study examines the levels of neutralizing antibodies against COVID-19 in health workers before and after the Quantitative Anti-SARS-CoV-2 Test is an examination to measure in vitro quantitative antibodies (including IgG) against the receptor binding domain (RBD) of the SARS-CoV Spike (S) protein. -2, which aims to assess the adaptive humoral immune response to the SARS-CoV-2 Spike protein. Measurement with the ECLIA method. Ratio Scale after the 2nd booster COVID-19 vaccine in Surakarta, Indonesia.

Also known as: COVID-19 Immunoglobulin

Health worker

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Health worker in Universitas Sebelas Maret Hospital, Surakarta, Indonesia

You may qualify if:

• Health workers who receive the second booster of COVID-19 vaccination

You may not qualify if:

• Pregnancy

Sponsors & Collaborators

• Universitas Sebelas Maret: lead

Study Sites (1)

Universitas Sebelas Maret Hospital

Sukoharjo, Central Java, 57161, Indonesia

Location

Related Publications (2)

• Pratama YS, Pradiptakirana R, Rachmah A, Prabowo NA. Autoimmune Thrombocytopenia in SLE and COVID-19. Eur J Case Rep Intern Med. 2021 Nov 3;8(11):002863. doi: 10.12890/2021_002863. eCollection 2021.

  PMID: 34912736 RESULT

• Sholihah MM, Kusuma TRH, Hanif MI, Prabowo NA. Letter to the Editor on Type 1 diabetes onset triggered by COVID-19. Acta Diabetol. 2021 Sep;58(9):1283-1284. doi: 10.1007/s00592-021-01761-3. Epub 2021 Jun 28. No abstract available.

  PMID: 34181079 RESULT

MeSH Terms

Conditions

COVID-19

Interventions

COVID-19 Serological Testing

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

COVID-19 Testing; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Serologic Tests; Immunologic Tests; Investigative Techniques; Immunologic Techniques

Study Officials

• Nurhasan Agung Prabowo, MD

  Universitas Sebelas Maret

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Head of Hospital Research Unit

Study Record Dates

• First Submitted: March 9, 2023
• First Posted: March 13, 2023
• Study Start: July 1, 2022
• Primary Completion: October 30, 2022
• Study Completion: November 30, 2022
• Last Updated: March 13, 2023

Record last verified: 2023-03

Data Sharing

• IPD Sharing: Will not share

Locations

ID (1)